Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carabersat SCHEMBL261192 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL29373163 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL9287969 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL27418709 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL3308650 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL3301553 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL3300409 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL27394684 | 1.00 | ABCC9 (0.62) | ABCC9 | |
| Carabersat SCHEMBL5317948 | 0.99 | ABCC9 (0.64) | ABCC9 | |
| Carabersat SCHEMBL5317945 | 0.99 | ABCC9 (0.64) | ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099752-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC. (GB) | 2010-04-22 | — | — | US | claimed |
| US-20070088064-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC | 2007-04-19 | — | — | US | claimed |
| US-20030236410-A1 | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEECHAM P.L.C. | 2003-12-25 | — | — | US | claimed |
| US-20020123630-A1 | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEECHAM P.L.C. | 2002-09-05 | — | — | US | claimed |
| US-20010021780-A1 | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEECHAM P.L.C. | 2001-09-13 | — | — | US | claimed |
| EP-0673374-B1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | EP | claimed |
| US-5948811-A | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEEGHAM P.L.C. (GB) | 1999-09-07 | — | — | US | claimed |
| EP-0673374-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | claimed |
| WO-1994013657-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | claimed |
| US-20160318891-A1 | TONABERSAT PRODRUGS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318891-A1 | TONABERSAT PRODRUGS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318891-A1 | TONABERSAT PRODRUGS | PROXIMAGEN LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3087063-A1 | TONABERSAT PRODRUGS | Proximagen Limited (GB) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015097463-A1 | TONABERSAT PRODRUGS | PROXIMAGEN LIMITED (GB) | 2015-07-02 | — | — | WO | disclosed |
| US-20020123630-A1 | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEECHAM P.L.C. | 2002-09-05 | — | — | US | disclosed |
| US-20010021780-A1 | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEECHAM P.L.C. | 2001-09-13 | — | — | US | disclosed |
| EP-0673374-B1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | EP | disclosed |
| US-5948811-A | Pharmaceutical composition containing bicyclic type compounds | SMITHKLINE BEEGHAM P.L.C. (GB) | 1999-09-07 | — | — | US | disclosed |
| EP-0673374-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013657-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236410-A1 | Pharmaceutical composition containing bicyclic type compounds | CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 | ABCC9 162/4885 |
| US-20070088064-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH, CBR3 | ABCC9 155/4885 |
| US-20160318891-A1 | TONABERSAT PRODRUGS | GPR119, F2R, QRFPR | ABCC9 791/4885 |
| US-20010021780-A1 | Pharmaceutical composition containing bicyclic type compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CLIC1, NAF1 | ABCC9 122/4885 |
| US-20100099752-A1 | PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS | SNCA, GRIN2C, PYGB | ABCC9 1314/4885 |
| US-20020123630-A1 | Pharmaceutical composition containing bicyclic type compounds | CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH | ABCC9 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.